spacer
small
primary
small
spacer
small
primary
small
spacer
small
primary
small
spacer
small
primary
small
backgroundColor
none
style
three-col-33-33-33
style
two-col-50-50
center
Different Patients, Different Needs, Different Medicines.
36px
Because having treatment options matters.
24px
sameTab
select
spacer
small
primary
small
backgroundColor
none
additionalPadding
none
additionalMargins
none
spacer
large
primary
small
left
28px
24px
one
spacer
medium
primary
small
left
28px

Foundayo is not indicated for cosmetic weight loss.
Zepbound should not be used for cosmetic weight loss.

16px
one
spacer
large
primary
small
left
28px

Beginning July 1, millions of eligible Medicare Part D patients can pay no more than $50 per month* for FoundayoTM (orforglipron) or Zepbound® (tirzepatide)1,2

48px
one
spacer
small
primary
small
backgroundColor
none
additionalPadding
none
additionalMargins
none
Graphic showing the cost per month for eligible patients withMedicare Part D as of July 1, 2026. This material contains AI-generated images.
A Foundayo patient holds a tablet and a Zepbound patient holds a KwikPen® for single-patient use, each pictured with the text "NO MORE THAN $50 PER MONTH." This material contains AI-generated images.
14px
spacer
small
primary
small
left
one
primary
Foundayo for your Medicare patient
link
https://foundayo.lilly.com/hcp/savings-coverage?tab=medicare
Foundayo for your Medicare patient
secondary
link
newTab
Graphic showing the cost per month for eligible patients with Medicare Part D as of July 1, 2026. This material contains AI-generated images.
A Foundayo patient holds a tablet and a Zepbound patient holds a KwikPen® for single-patient use, each pictured with the text "NO MORE THAN $50 PER MONTH." This material contains AI-generated images.
spacer
small
primary
small
left
two
primary
Zepbound for your Medicare patient
link
https://zepbound.lilly.com/hcp/medicare
Learn more about Zepbound for your Medicare patient
vertical
secondary
asset
newTab
backgroundColor
none
style
two-col-50-50
spacer
large
primary
small
style
two-col-50-50
left
one
Prescribing Guide
asset
https://delivery-p137454-e1438138.adobeaemcloud.com/adobe/assets/urn:aaid:aem:c11dd4ec-5a2d-467f-bdf7-a106863e9513/renditions/original/as/CMAT-30456-Digital_Medicare_HCP_Resource.pdf?assetname=CMAT-30456-Digital_Medicare_HCP_Resource.pdf
backgroundColor
none
additionalPadding
none
additionalMargins
none
spacer
large
primary
small
right
*Terms apply. Injection supplies sold separately.
20px
one
divider
large
primary
small
spacer
large
primary
small
left
Your adult patients will have coverage for Foundayo and Zepbound® KwikPen® for single-patient use as part of Medicare GLP-1 Bridge between July 1, 2026 - December 31, 2027, if they meet the following criteria at the time of initiation of therapy2:
20px
one
spacer
large
primary
small
true
true
true
backgroundColor
none
style
three-col-33-33-33
spacer
small
primary
small
left

These eligibility criteria are Medicare GLP-1 Bridge defined access requirements and may not reflect the Foundayo or Zepbound product labels or clinical trial populations.

For eligible Medicare patients with a Foundayo or Zepbound prescription. This information is not a guarantee of coverage. Actual eligibility will be determined by Medicare GLP-1 Bridge eligibility criteria. Visit https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge to learn more.

20px
BMI=body mass index; CKD=chronic kidney disease; CMS=Centers for Medicare & Medicaid Services; GLP-1=glucagon-like peptide-1; HFpEF=heart failure with preserved ejection fraction; MI=myocardial infarction; PAD=peripheral arterial disease
14px
one
spacer
large
primary
small
backgroundColor
none
additionalPadding
none
additionalMargins
none
divider
small
primary
small
spacer
medium
primary
small
backgroundColor
none
additionalPadding
none
additionalMargins
none
left

INDICATION

Foundayo is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

Limitations of Use: Concomitant use with another GLP-1 receptor agonist is not recommended.

20px
one
spacer
medium
primary
small
left
WARNING: RISK OF THYROID C-CELL TUMORS

In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined.

Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Foundayo and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Foundayo.
20px
one
left

INDICATIONS

Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity:

  • to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
  • to treat moderate-to-severe-obstructive sleep apnea (OSA) in adults with obesity.

Limitations of Use:  Zepbound contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

20px
one
spacer
medium
primary
small
left

WARNING: RISK OF THYROID C-CELL TUMORS

In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Zepbound and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Zepbound.

20px
one
style
two-col-50-50
spacer
medium
primary
small
divider
medium
primary
small
backgroundColor
none
additionalPadding
none
additionalMargins
none
Icon of a group of 5 people with 2 people highlighted in red
left
In the US, nearly 2 in 5 adults aged 65+ have obesity3
36px
As obesity prevalence increases, people aged 65+ may face increased risk of weight-related complications.3
20px
spacer
medium
primary
small
left
Based on data collected by the National Health and Nutrition Examination Survey observing the percentage of the population aged 65 and over with obesity. Data were collected in the following time intervals: 1988-1994,1999-2002, 2003-2006, 2007-2010, 2011-2014, 2015-2018, and 2021-2023.3
20px
one
backgroundColor
none
additionalPadding
narrow
additionalMargins
narrow
backgroundColor
none
additionalPadding
none
additionalMargins
none
center
24px
one
text
Sources
backgroundColor
none
additionalPadding
none
additionalMargins
none
spacer
small
primary
small
left
16px

1. Sexton Ward A, Tysinger B, Nguyen P, Goldman D, Lakdawalla D. Benefits of Medicare coverage for weight loss drugs. USC Leonard D. Schaeffer Institute for Public Policy & Government Service. Published April 18, 2023. Accessed March 16, 2026. https://schaeffer.usc.edu/research/benefits-of-medicare-coverage-for-weight-loss-drugs/

2. Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge. Updated April 21, 2026. Accessed April 22, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

3. Federal Interagency Forum on Aging-Related Statistics. Older Americans: key indicators of well-being. Published May 2024. Accessed February 4, 2026. https://agingstats.gov/docs/LatestReport/Older-Americans-2024-508-May-update.pdf

one
spacer
small
primary
small
text
Sources
backgroundColor
none
additionalPadding
none
additionalMargins
none